Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    No significant additions or deletions detected in the core study information (title, condition, interventions, outcomes, eligibility, or enrollment). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T13:05:52.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    35 days ago
    Change Detected
    Summary
    The page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.
    Difference
    2%
    Check dated 2025-10-05T17:42:30.000Z thumbnail image
  4. Check
    43 days ago
    Change Detected
    Summary
    Removed several disease/classification terms (neoplasms and carcinoma-related entries) and added a version update to v3.1.0.
    Difference
    0.5%
    Check dated 2025-09-28T11:17:07.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    The page revision updates from v3.0.1 to v3.0.2. The 'Back to Top' UI element has been removed.
    Difference
    0.1%
    Check dated 2025-09-14T00:52:21.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The web page has been updated from version v3.0.0 to v3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-06T21:27:42.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has added significant medical content related to various diseases, particularly focusing on female urogenital conditions and neoplasms, while removing several related resources and terms.
    Difference
    4%
    Check dated 2025-08-30T15:59:23.000Z thumbnail image

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.